Myasthenia Gravis
Conditions
Interventions
Patients with MG type II:-
healthy individuals:-
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for MG patients: 1) Age between 18-75 years old, male and female; 2) Referring to the MG diagnostic criteria of the 2020 Chinese Guidelines for the Diagnosis and Treatment of Myasthenia Gravis, and according to the clinical typing of the Myasthenia Gravis Foundation of America (MGFA), patients with MG type II were selected as the study subjects; 3) Using the above diagnosis as the first diagnosis for admission; 4) Those who were not admitted with MG as the first diagnosis, but had a history of MG and whose first diagnosis was closely related to the recurrence, exacerbation, and treatment of MG (e.g., infection, etc.); 5) Complete clinical history data; 6) Agree to participate in this study and sign the informed consent form. 2. Healthy volunteers inclusion criteria: 1) Age between 18-75 years old, male and female; 2) No history of MG; 3) Agree to participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1) Those whose first diagnosis on admission was not MG and whose reason for hospitalization was not related to MG recurrence, exacerbation, or treatment; 2) Those with incomplete clinical history data; 3) Those who combine other systematic serious diseases, such as psychiatric diseases, cerebrovascular diseases, cardiac, hepatic and renal failure, malignant tumors, etc. 4) Congenital and family hereditary myasthenia gravis, myasthenia gravis crisis; 5) Combined rheumatic, human immunodeficiency virus and other autoimmune diseases; 6) Patients have participated in other clinical studies in the past month; 7) Treatment with plasma exchange or intravenous gammaglobulin within the past 3 months; 8) Pregnant or lactating women, or those of childbearing potential who are unwilling/unable to use effective contraception.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| key signaling pathway indicators of ferroptosis (PRDX2, MFN2, ACSL4);iron metabolism indicators (total iron and Fe2+, TF, TFR1, FtMt);lipid peroxidation indicators (4-HNE, MDA, LPCAT3, LOX15);glycosylation indicators (O-GlcNAc, OGT, OGA); | — |
Countries
China
Contacts
Public ContactLina Zhao
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed